ENV105
Prostate Cancer
Key Facts
About Kairos Pharma
Kairos Pharma is a private, clinical-stage biotech focused on overcoming two major challenges in oncology: acquired drug resistance and immune suppression. Its core platform targets the CD105 protein, identified as a central mechanism of resistance to therapies in prostate and lung cancers, and develops complementary immunomodulatory technologies. With its lead asset, ENV105, in Phase 2 trials for prostate cancer and Phase 1 for lung cancer, the company is positioned to address a significant unmet need across multiple solid tumors, backed by intellectual property protection extending to 2040.
View full company profileAbout Kairos Pharma
Kairos Pharma is a private, clinical-stage biotech focused on overcoming two major challenges in oncology: acquired drug resistance and immune suppression. Its core platform targets the CD105 protein, identified as a central mechanism of resistance to therapies in prostate and lung cancers, and develops complementary immunomodulatory technologies. With its lead asset, ENV105, in Phase 2 trials for prostate cancer and Phase 1 for lung cancer, the company is positioned to address a significant unmet need across multiple solid tumors, backed by intellectual property protection extending to 2040.
View full company profileAbout Kairos Pharma
Kairos Pharma is a private, clinical-stage biotech focused on overcoming two major challenges in oncology: acquired drug resistance and immune suppression. Its core platform targets the CD105 protein, identified as a central mechanism of resistance to therapies in prostate and lung cancers, and develops complementary immunomodulatory technologies. With its lead asset, ENV105, in Phase 2 trials for prostate cancer and Phase 1 for lung cancer, the company is positioned to address a significant unmet need across multiple solid tumors, backed by intellectual property protection extending to 2040.
View full company profileTherapeutic Areas
Other Prostate Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO442 | Aptevo Therapeutics | Preclinical |
| APVO452 | Aptevo Therapeutics | Discovery |
| BIO 300 | Humanetics Corp. | Not Specified |
| Opaganib | RedHill Biopharma | Phase 2 |
| MagSense™ PSMA Imaging Agent | Imagion Biosystems | Pre‑clinical |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| Leronlimab | CytoDyn | Preclinical |
| CROES Registry | AngioDynamics | Post-Market Registry |
| Cannabics® PRST-33 | CNBX Pharmaceuticals | Discovery |
| HDP-103 | Heidelberg Pharma | Preclinical |
| AI for Prostate Cancer | Invenio Imaging | Research |
| Mitomic™ Test for Prostate Cancer | MDNA Life Sciences | Development/Validation |